FSD Pharma Inc. (HUGE) – Business Wire
-
FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)
-
Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201
-
FSD Pharma Retains Christian Attar Law and Team of Experts to Lead Preliminary Investigation of Possible Naked Short Selling and Manipulation in its stock
-
FSD Pharma Appoints Zeeshan Saeed as Chief Executive Officer, Anthony Durkacz to Serve as Executive Co-Chairman of the Board of Directors
-
FSD Pharma Inc. Announces Results of Annual General and Special Meeting of Shareholders
-
FSD Pharma Announces Agreement to Grant Exclusive Rights to Revolutionary Recreational Alcohol Misuse Technology
-
FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors
-
FSD Pharma Announces Receipt of Court Action and Update on Spin-Out and Distribution
-
FSD Pharma Awarded $2.81 Million in Cost Awards From Dr. Raza Bokhari
-
FSD Pharma Completes Dosing of First Cohort in Phase I Clinical Trial of Lucid-MS, a New Drug Candidate for the Treatment of Multiple Sclerosis: Safety Review Committee Recommends Commencing Dosing of
-
FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
-
FSD Pharma Achieves Milestone in Completion of Dosing of Sentinel Subjects in First-in-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis
-
FSD Pharma Announces Plan to Spin-Out Subsidiary as Distribution to Shareholders; Shareholder Meeting Scheduled for June 29, 2023
-
FSD Pharma Announces Filing of Year-End 2022 Results
-
FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors
-
FSD Pharma Announces Its Australian Entity Receives Approval to Proceed With Phase 1 Clinical Trial of Lucid-201, a Candidate for the Potential Treatment of Major Depressive Disorder
-
FSD Pharma (Symbol: HUGE) Renews Shareholder Intelligence Services to Investigate Possible Naked Short Selling and Appeals to The Regulators and Oversight Bodies to Look Into The Short Selling Activit
-
Original “Shark” and Iconic Entrepreneur Kevin Harrington Joins FSD Pharma Advisory Board
-
FSD Pharma Presenting Two Scientific Posters on Preclinical Toxicology and Efficacy Data of Lucid-21-302 (Lucid-MS) at Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) 202
-
FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements
-
FSD Pharma Launches A New Research and Development Program Targeting Unmet Medical Needs for Alcohol Misuse
-
FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate
-
Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
-
FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation
-
FSD Pharma Announces Share Repurchase Program
-
FSD Pharma Inc Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia
-
FSD Pharma to Attend 41st Annual J.P. Morgan Healthcare Conference 2023
-
FSD Pharma Announces Changes to the Board of Directors
-
FSD Pharma Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari
-
FSD Pharma Inc. Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
-
FSD Pharma Participating in H.C. Wainwright 24th Annual Global Investment Conference, On-Demand Presentation Available
-
FDA and Health Canada Clear IND for FSD Pharma to Proceed with Phase 2 Trial of FSD201 for Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome
-
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent On Novel Formulations of Palmitoylethanolamide, Presents Preclinical Toxicology Results at an International Symposium
-
FSD Pharma Inc. Announces Results of Annual General Meeting of Shareholders And Other Corporate Updates
-
FSD Pharma Files Investigational New Drug Application (“IND”) with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory disorder and Provides Corporate Updates
-
FSD Pharma Issues Circular, Adopts Incentive Plan and Grants PSUs
-
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
-
FSD Pharma Announces Dismissal of Derivative Complaint
-
FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates
-
FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board
-
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari
-
FSD Pharma Issues Corporate Updates
-
FSD Pharma Announces Filing of Year-End 2021 Results
-
FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC
-
FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000
-
FSD Pharma Announces Launch of New Corporate Website
-
FSD Pharma Congratulates Dr. Eleanor Fish on Being Named to the Order of Canada
-
FSD Pharma to Present at the H.C. Wainwright Bioconnect Conference on January 10-13th
-
FSD Pharma Announces Share Repurchase Program
-
FSD Pharma Establishes New Regulatory Advisory Board with the Appointment of Joga Gobburu, Ph.D., and Mary Melnyk, Ph.D., as Members
Back to HUGE Stock Lookup
